Chong Kun Dang announces domestic exclusive sales agreement of lupus treatment
O
n the 14th, Chong Kun Dang(CEO Young-joo Kim) announced the domestic exclusive sales agreement of ‘IFN-K(interferenon-α-kinoid), a systemic lupus erythematosus(hereinafter referring to lupus), with French Neoxacs.
IFN-K is a treatment vaccine whose phase 2 clinical trials are being process by N...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
